BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists. 2013

Satoshi Yamamoto, and Hiromi Kobayashi, and Tomohiro Kaku, and Katsuji Aikawa, and Takahito Hara, and Masuo Yamaoka, and Naoyuki Kanzaki, and Atsushi Hasuoka, and Atsuo Baba, and Mitsuhiro Ito
Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan. satoshi.yamamoto@takeda.com

We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide.

UI MeSH Term Description Entries
D008297 Male Males
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011467 Prostate A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM. Prostates
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D011944 Receptors, Androgen Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA. Androgen Receptors,5 alpha-Dihydrotestosterone Receptor,Androgen Receptor,Dihydrotestosterone Receptors,Receptor, Testosterone,Receptors, Androgens,Receptors, Dihydrotestosterone,Receptors, Stanolone,Stanolone Receptor,Testosterone Receptor,5 alpha Dihydrotestosterone Receptor,Androgens Receptors,Receptor, 5 alpha-Dihydrotestosterone,Receptor, Androgen,Receptor, Stanolone,Stanolone Receptors,alpha-Dihydrotestosterone Receptor, 5
D002369 Castration Surgical removal or artificial destruction of gonads. Gonadectomy,Castrations,Gonadectomies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Satoshi Yamamoto, and Hiromi Kobayashi, and Tomohiro Kaku, and Katsuji Aikawa, and Takahito Hara, and Masuo Yamaoka, and Naoyuki Kanzaki, and Atsushi Hasuoka, and Atsuo Baba, and Mitsuhiro Ito
Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.
January 2012, Bioorganic & medicinal chemistry,
Satoshi Yamamoto, and Hiromi Kobayashi, and Tomohiro Kaku, and Katsuji Aikawa, and Takahito Hara, and Masuo Yamaoka, and Naoyuki Kanzaki, and Atsushi Hasuoka, and Atsuo Baba, and Mitsuhiro Ito
Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists.
April 2012, Bioorganic & medicinal chemistry,
Satoshi Yamamoto, and Hiromi Kobayashi, and Tomohiro Kaku, and Katsuji Aikawa, and Takahito Hara, and Masuo Yamaoka, and Naoyuki Kanzaki, and Atsushi Hasuoka, and Atsuo Baba, and Mitsuhiro Ito
Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
June 2015, European journal of medicinal chemistry,
Satoshi Yamamoto, and Hiromi Kobayashi, and Tomohiro Kaku, and Katsuji Aikawa, and Takahito Hara, and Masuo Yamaoka, and Naoyuki Kanzaki, and Atsushi Hasuoka, and Atsuo Baba, and Mitsuhiro Ito
Design, synthesis, and biological evaluation of 2-(phenoxyaryl)-3-urea derivatives as novel P2Y1 receptor antagonists.
October 2018, European journal of medicinal chemistry,
Satoshi Yamamoto, and Hiromi Kobayashi, and Tomohiro Kaku, and Katsuji Aikawa, and Takahito Hara, and Masuo Yamaoka, and Naoyuki Kanzaki, and Atsushi Hasuoka, and Atsuo Baba, and Mitsuhiro Ito
Synthesis and biological evaluation of 3-(4-fluorophenyl)-1H-pyrazole derivatives as androgen receptor antagonists.
April 2016, Anti-cancer drugs,
Satoshi Yamamoto, and Hiromi Kobayashi, and Tomohiro Kaku, and Katsuji Aikawa, and Takahito Hara, and Masuo Yamaoka, and Naoyuki Kanzaki, and Atsushi Hasuoka, and Atsuo Baba, and Mitsuhiro Ito
Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
September 2015, European journal of medicinal chemistry,
Satoshi Yamamoto, and Hiromi Kobayashi, and Tomohiro Kaku, and Katsuji Aikawa, and Takahito Hara, and Masuo Yamaoka, and Naoyuki Kanzaki, and Atsushi Hasuoka, and Atsuo Baba, and Mitsuhiro Ito
Design, synthesis and biological evaluation of novel biphenylsulfonamide derivatives as selective AT2 receptor antagonists.
January 2022, Frontiers in chemistry,
Satoshi Yamamoto, and Hiromi Kobayashi, and Tomohiro Kaku, and Katsuji Aikawa, and Takahito Hara, and Masuo Yamaoka, and Naoyuki Kanzaki, and Atsushi Hasuoka, and Atsuo Baba, and Mitsuhiro Ito
Design, synthesis and biological evaluation of 3-aryl-7-hydroxy scopoletin derivatives as autophagy activators against tumorigenesis.
December 2022, European journal of medicinal chemistry,
Satoshi Yamamoto, and Hiromi Kobayashi, and Tomohiro Kaku, and Katsuji Aikawa, and Takahito Hara, and Masuo Yamaoka, and Naoyuki Kanzaki, and Atsushi Hasuoka, and Atsuo Baba, and Mitsuhiro Ito
Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.
February 2021, Bioorganic & medicinal chemistry,
Satoshi Yamamoto, and Hiromi Kobayashi, and Tomohiro Kaku, and Katsuji Aikawa, and Takahito Hara, and Masuo Yamaoka, and Naoyuki Kanzaki, and Atsushi Hasuoka, and Atsuo Baba, and Mitsuhiro Ito
Design, synthesis and biological evaluation of novel piperazine derivatives as CCR5 antagonists.
January 2013, PloS one,
Copied contents to your clipboard!